전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,132 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleShenzhen Geno-Immune Medical In…Preclinical

Therapeutic 4SCAR19 cells (Therapeutic 4SCAR19 cells)

B-cell Malignancies · B-cell Malignancies

#B-cellMalignancies#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
CGTLimited DatastaleWuhan Bio-Raid Biotechnology Co…Phase 1

Third generation CAR-T cells (Third generation CAR-T cells)

B Cell Lymphoma; Acute Lymphoblastic Leukemia · B Cell Lymphoma

#BCellLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleWuhan Bio-Raid Biotechnology Co…Phase 1

Third-generation anti-CD123 CAR-T cells (Third-generation anti-CD123 CAR-T cells)

CD123+ Acute Myeloid Leukemia · CD123+ Acute Myeloid Leukemia

#CD123+AcuteMyeloidLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleFundamenta Therapeutics, Ltd.Phase 1

ThisCART19 cells (ThisCART19 cells)

B Cell Malignancy · B Cell Malignancy

#BCellMalignancy#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleFundamenta Therapeutics, Ltd.Phase 1

ThisCART22 cells (ThisCART22 cells)

B-cell Malignancy · B-cell Malignancy

#B-cellMalignancy#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleFundamenta Therapeutics, Ltd.Phase 1

ThisCART7 cells (ThisCART7 cells)

T-Acute Lymphoblastic Leukemia; T-cell Non-Hodgkin Lymphoma · T-Acute Lymphoblastic Leukemia

#T-AcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleRuijin HospitalPhase 2

Tirelizumab (Tirelizumab)

Esophageal Squamous Cell Carcinoma · Esophageal Squamous Cell Carcinoma

#EsophagealSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Ruijin
Trials 1Status Recruiting
AntibodyLimited DatastaleChugai PharmaceuticalPhase 1

Tocilicumab (Tocilicumab)

Hepatocellular Carcinoma (HCC) · Hepatocellular Carcinoma (HCC)

#HepatocellularCarcinomaHCC#Antibody#Phase1#monoclonal-antibody#Chugai
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Tocilizumab before CAR-T cell infusion (Tocilizumab before CAR-T cell infusion)

Myeloma; Lymphoma · Myeloma

#Myeloma#Antibody#Phase2#monoclonal-antibody#Lymphoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleDaping Hospital and the Researc…Phase 2

PCSK9 Inhibitor (Tolecizumab, Tolecizumab (PCSK9 Inhibitor))

Colon Adenocarcinoma · Colon Adenocarcinoma

#ColonAdenocarcinoma#Antibody#Phase2#monoclonal-antibody#Daping
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab+cetuximab (Toripalimab+cetuximab)

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma · Patients With Locally Recurrent Resectab

#PatientsWithLocallyRecurrentRese#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleNorthwestern UniversityPhase 1

Transferrin Receptor-Targeted Liposomal p53 cDNA (Transferrin Receptor-Targeted Liposomal p53 cDNA)

Anatomic Stage IV Breast Cancer AJCC v8; Breast Inflammatory Carcinoma · Anatomic Stage IV Breast Cancer AJCC v8

#AnatomicStageIVBreastCancerAJCCv#Antibody#Phase1#monoclonal-antibody#BreastInflammatoryCarcinoma+1
Trials 1Status Discontinued
ADCLimited DatastaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan + FLO)

Esophagogastric Adenocarcinoma · Esophagogastric Adenocarcinoma

#EsophagogastricAdenocarcinoma#ADC#Phase2#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting
ADCLimited DatastaleBoryung Pharmaceutical Co., LtdPhase 2

Trastzumab Deruxtecan (Trastzumab Deruxtecan)

Ovarian Cancer; Ovarian Carcinoma, Recurrent · Ovarian Cancer

#OvarianCancer#ADC#Phase2#antibody-drug-conjugate#OvarianCarcinoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

MEDI4736 (Tremelimumab Plus Durvalumab, Tremelimumab Plus Durvalumab (MEDI4736))

Hepatocellular Carcinoma (HCC); Unresectable Hepatocellular Carcinoma · Hepatocellular Carcinoma (HCC)

#HepatocellularCarcinomaHCC#Antibody#Phase2#monoclonal-antibody#UnresectableHepatocellularCarcin+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

Tremelimumab immunotherapy (Tremelimumab immunotherapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#AstraZeneca
Trials 1Status Recruiting
CGTLimited DatastaleTimmune Biotech Inc.Phase 2

TriCAR-T-CD19 (TriCAR-T-CD19)

Non-hodgkin Lymphoma,B Cell · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleQuantumLeap Healthcare Collabor…Phase 2

trastuzumab (Herceptin, Trilaciclib with or without trastuzumab + pertuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Recruiting
CGTLimited DatastaleShanghai Unicar-Therapy Bio-med…Phase 1

Triple-targeted CAR-T Therapy (Triple-targeted CAR-T Therapy)

B-cell Lymphoma · B-cell Lymphoma

#B-cellLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

Tucidinostat (Tucidinostat, Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, chidamide)

Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#EsophagealSquamousCellCancer+3
Trials 1Status Active

51 / 57 pages

← PreviousNext →